Xiehe Yixue Zazhi (Nov 2021)

Investigation and Evaluation of Chinese Clinical Practice Guidelines Published in Medical Journals in 2019: Analysis of the Evidence

  • LIU Xiao,
  • YANG Nan,
  • WU Shouyuan,
  • GUO Qiangqiang,
  • LIU Hui,
  • SUN Yajia,
  • WANG Jianjian,
  • ZHOU Qi,
  • WANG Zijun,
  • SHI Qianling,
  • ZHAO Siya,
  • LI Qinyuan,
  • LUO Xufei,
  • LYU Meng,
  • SONG Xuping,
  • CHEN Yaolong

DOI
https://doi.org/10.12290/xhyxzz.2021-0624
Journal volume & issue
Vol. 12, no. 6
pp. 1016 – 1021

Abstract

Read online

Objective To investigate the current status of evidence of recommendations contained in Chinese clinical practice guidelines published in journals in 2019, so as to provide reference for the use of evidence for Chinese guidelines in the future. Methods We searched and analyzed information on Chinese guidelines published in 2019 with clear recommendations, grading of evidence quality and corresponding instructions of grading, as well as information on citations supporting the recommendations. Results A total of 31 guidelines (29 Chinese guidelines and 2 English guidelines) containing 568 recommendations and 3126 references were included. Each guideline included an average of 18 recommendations. Of these, 2541 references were presented as evidence in the statements of guideline recommendation(such references are referred to as 'evidence' hereafter). The average number of evidence was 82 in each guideline and every recommendation has 4 pieces of evidence. The top three countries where the evidence was from were China (28.8%), the United States (25.9%), and the United Kingdom (7.0%). Only 39.2% (995/2541) of the evidence was published in the last 5 years. The most common type of evidence for guidelines was randomized controlled trials (26.9%). The citation of systematic reviews was only 12.0%. Conclusions Most of the Chinese guidelines published in 2019 did not have clear and unambiguous recommendations. Those guidelines with clear recommendations had incomplete and untimely evidence citations. Guideline developers should strengthen the rational use of currently available research evidence.

Keywords